MAPK3 and lymphoma: PI3K/Akt/mTOR is an important pathway in DLBCL, considering that its inhibition results in antilymphoma activity both in vivo and in vitro, suggesting that Akt is a potential target for DLBCL treatment.34, 35 The ERK1/2 pathway also has a crucial role in cell proliferation, differentiation, apoptosis and migration, which has been verified in lymphoma cells.36 Data from the current study showed that DCZ3301 inhibits the Akt pathway while activating the ERK pathway.